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Background. Pre-mRNA splicing, the removal of introns from RNA, takes place within the spliceosome, a macromolecular
complex composed of five small nuclear RNAs and a large number of associated proteins. Spliceosome assembly is modulated
by the 59 and 39 splice site consensus sequences situated at the ends of each intron, as well as by exonic and intronic splicing
enhancers/silencers recognized by SR and hnRNP proteins. Nonsense mutations introducing a premature termination codon
(PTC) often result in the activation of cellular quality control systems that reduce mRNA levels or alter the mRNA splicing
pattern. The mdx mouse, a commonly used genetic model for Duchenne muscular dystrophy (DMD), lacks dystrophin by virtue
of a premature termination codon (PTC) in exon 23 that also severely reduces the level of dystrophin mRNA. However, the
effect of the mutation on dystrophin RNA processing has not yet been described. Methodology/Principal Finding. Using
combinations of different biochemical and cellular assays, we found that the mdx mutation partially disrupts a multisite exonic
splicing enhancer (ESE) that is recognized by a 40 kDa SR protein. In spite of the presence of an inefficient intron 22 39 splice
site containing the rare GAG triplet, the mdx mutation does not activate nonsense-associated altered splicing (NAS), but
induces exclusively nonsense-mediated mRNA decay (NMD). Functional binding sites for SR proteins were also identified in
exon 22 and 24, and in vitro experiments show that SR proteins can mediate direct association between exon 22, 23, and 24.
Conclusions/Significance. Our findings highlight the complex crosstalk between trans-acting factors, cis-elements and the
RNA surveillance machinery occurring during dystrophin mRNA processing. Moreover, they suggest that dystrophin exon–
exon interactions could play an important role in preventing mdx exon 23 skipping, as well as in facilitating the pairing of
committed splice sites.
Citation: Buvoli M, Buvoli A, Leinwand LA (2007) Interplay between Exonic Splicing Enhancers, mRNA Processing, and mRNA Surveillance in the
Dystrophic Mdx Mouse. PLoS ONE 2(5): e427. doi:10.1371/journal.pone.0000427
INTRODUCTION
Dystrophin is a 427 kDa structural protein that connects the actin
cytoskeleton with the basal lamina and protects the myofibers from
mechanical stress produced during muscle contraction [1,2].
Mutations in the very large dystrophin gene (2.4 million bases) are
associated with both Duchenne muscular dystrophy (DMD),
characterized by severe and progressive muscle degeneration,
and the milder Becker muscular dystrophy (BMD). Dystrophin
gene expression is controlled by several independent promoters,
alternative splicing, and the use of different polyA
+ signals.
Although the gene covers about 2.4 megabases on the short arm of
the X chromosome [3,4], the 79 exons only encode a 14 kb
mRNA [5]. Thus, 99.4% of hnRNA corresponds to intervening
sequences that have to be removed during the splicing reaction.
Pre-mRNA splicing consists of two consecutive trans-esterification
reactions, and is carried out by the spliceosome, an RNA-protein
complex composed of five small ribonucleoparticles called snRNPs
and a large number of non-snRNP splicing factors [6,7].
Splice site selection occurs by precise identification of poorly
conserved consensus sequences located at the intron-exon
boundaries. Commitment for a given set of splice sites appears
to be enhanced by protein cross-talk across each exon, a process
called exon definition [8], and by repression of numerous
pseudosplice sites that are usually present in primary transcripts
[9]. Specific cis-elements located in the exons, known as exonic
splicing enhancers (ESEs), promote both constitutive and regulat-
ed splicing [10] and appear to be involved in exon definition [11].
Although ESEs were initially identified in alternative spliced exons
as purine-rich regions [12–15], different motifs have been
identified by different iterative selection strategies [16–19].
ESEs are recognized by SR proteins, a group of highly
conserved modular splicing factors containing a N-terminal
RNA-recognition domain (RRM), that mediates RNA binding,
and a C-terminal arginine/serine rich domain, required for
protein-protein interactions [20]. When bound to ESEs, SR
proteins recruit and facilitate the binding of different components
of the spliceosome to the nearby intron [10,21,22]. Moreover, they
promote spliceosome assembly by directly contacting the pre-
mRNA [23–25], as well as splice site selection by bringing exons
into proximity [26,27].
Even though the majority of ESEs have been found in
enhancer-dependent introns containing a weak splice site, their
discovery in constitutive exons [28–33], together with the finding
that protein-coding sequences are enriched for potential SR
binding sites [34–37], suggests that they could be present in the
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silent, and nonsense mutations, promotes exon skipping, intron
retention, or exon size reduction. This process is different from the
controversial nonsense–associated altered splicing (NAS), a post-
transcriptional control pathway that detects disruptions in the
open reading frame of precursor mRNAs. By regulating the
synthesis of alternatively spliced isoforms skipping the nonsense
mutation, NAS could prevent the production of deleterious
truncated proteins [38–43]. While NAS affects only the splicing
process, nonsense-mediated mRNA decay (NMD), the primary
cellular response to mRNA carrying a premature termination
codon (PTC), rapidly degrades fully spliced transcripts. NMD is
activated during the first round of translation by PTCs placed
at.50–55 nucleotides from the last exon–exon junction that is
marked, after splicing, with an exon junction complex (EJC) that
interacts with the termination factors [44–46].
The mdx mouse, the most widely used animal model for
Duchenne muscular dystrophy, carries an ochre nonsense
mutation in dystrophin exon 23 [47] that drastically reduces the
abundance of dystrophin mRNA and consequently abolishes
dystrophin expression [48]. Interestingly, a rare G residue
precedes the terminal dinucleotide AG of intron 22, a configura-
tion that is also present in the wild type strain. In vitro, GAG does
not appear to function efficiently for the second step of splicing,
and CAG to GAG mutations often result in exon skipping in vivo
[49–54]. These findings explain the very low presence of GAG
trinucleotides at natural 39 splice sites [55].
A promising RNA ‘‘re-framing’’ strategy based on antisense
oligonucleotides that promote skipping of exons carrying nonsense
mutations has recently been developed and tested in the mdx
mouse system [56]. However, the potential impact of the mdx
mutation on dystrophin mRNA processing has not yet been
examined. In this study we investigated the molecular events
triggered by the mdx mutation on mRNA metabolism, the
functional activity of the GAG present in intron 22, and the
potential relevance of SR proteins on dystrophin mRNA splicing.
RESULTS
Identification of dystrophin exon 23 splicing
enhancers
Since it has been reported that ESEs are present in several
dystrophin exons and their inactivation can cause perturbations in
the gene splicing pattern [28,57–59], we began our analysis by
determining whether exon 23 contains ESEs. To this aim, different
regions of the exon 23 were cloned into the enhancer-dependent
Dpy2 pre-mRNA [60], an heterologous construct that carries
a weak polypyrimidine tract and does not splice in vitro (Figure 1,
Dpy2). A minimal region, capable of activating Dpy2 splicing in
vitro, was mapped to the first 90 nucleotides of exon 23 (Figure 1,
D90). The mdx CRT transversion located in a 12 nucleotides
conserved region (M1element), did not disrupt any of the potential
high-score SR motifs for SF2/ASF, SC35, SRp40 and SRp55
[61,62] but reduced D90 splicing more than 40% (Figure 1,
D90mdx). Mutagenesis of a purine-rich region (R1 element)
matching a splicing enhancer previously identified by in vitro
selection [16,18], completely abolished splicing activation
(Figure 1, D90R1M) that was not restored by downstream exonic
sequences (data not shown). To define further the ESE, we
determined that the first 40 nucleotides of exon 23 containing only
M1, did not activate Dpy2 splicing (data not shown). However,
their deletion abolished Dpy2 activation (Figure 1, D1-40D)
suggesting that the exon 23 ESE is a multipartite enhancer
consisting of two elements, M1 and R1. Finally, when compared
with the well-characterized a-tropomyosin exon 2 enhancer
elements (Dpy2E construct), exon 23 ESE stimulated Dpy2
splicing less efficiently (2.5 fold reduction).
These data indicate that the constitutive dystrophin exon 23
contains a multisite-ESE that is partially inactivated by the mdx
nonsense mutation. Thus, reduction of dystrophin mRNA levels
observed in the mdx mouse could result from aberrant splicing
caused by the disruption of this splicing cis-element.
SR proteins interact with dystrophin exon 23
splicing enhancer
SR proteins bound to ESEs promote spliceosome assembly and
pre-mRNA processing. To determine whether SR proteins could
form a stable complex with the exon 23 ESE, an RNA mobility
shift assay was performed. As shown in Figure 2, a retarded RNA-
protein complex was resolved on a native gel following incubation
of
32P-labeled D90 RNA and calf thymus purified SR proteins
(second lane from left). An excess of D90 cold competitor
successfully prevented the efficient formation of the complex,
whereas the competitor carrying the mdx mutation (D90mdx) was
much less effective. In contrast, the double mutant D90mdxR1M
was unable to significantly inhibit complex formation even at the
highest concentration of competitor tested. Thus, SR proteins
specifically bind exon 23 ESE and could mediate the enhancing
activity of D90 observed in the heterologous Dpy2 construct. As
judged by the effect of the D90mdx competitor on complex
formation, it appears that the mdx mutation interferes with SR
assembly on exon 23 ESE.
UV cross-linking experiments were then carried out to
determine which SR protein(s) might directly contact the M1
and/or the R1 elements. Uniformly
32P-labeled D90 RNA was
incubated with purified SR proteins, UV irradiated and RNase
digested as described in the Materials and Methods section. The
resulting radioactive complexes were then resolved by SDS-
PAGE. As shown in Figure 3A, a 40 kDa SR protein was
efficiently cross-linked to the first 90 nucleotides of exon 23
containing both M1 and R1 (D90). A reduction in complex
formation was observed after deletion of R1 (D90DR1), confirm-
ing the functional relationship between M1 and R1 previously
observed in the in vitro splicing reaction. A 40 kDa protein was also
the only polypeptide cross-linked to the whole exon 23 RNA
(D23). Nevertheless, the comparison between the intensity of the
D90DR1 and D23DR1 signals (with a difference of about 2.5 fold)
strongly suggests that another 40 kDa protein binding site is
located downstream of D90. Binding specificity for the M1 and R1
sites was then demonstrated by the addition to the reactions of the
mutant cold competitors D90mdx and D90R1M. As shown in
Figure 3B, both RNAs had a similar effect in reducing the 40 kDa
cross-linking when compared with the wild type D90. Selective
enrichment of the 40 kDa protein in our SR preparation was ruled
out by Coomassie-stained SDS-PAGE gel that showed the
expected SR protein relative ratio (Figure 3C, SR lane) [63].
Thus, the natural mdx mutation could impair splicing efficiency by
reducing the binding of a 40 kDa SR protein to exon 23 ESE.
In vivo analysis of mutations affecting exon 23 ESE
activity
The relevance of the mdx and R1 mutations and their potential
effects on dystrophin mRNA metabolism were next studied in cell
culture. COS 7 cells were transfected with model substrates
carrying different portions of the dystrophin gene. Two-exon
constructs, containing the genomic sequence spanning from exon
22 to exon 23, were utilized to study the effect of the mutations on
Dystrophin mRNA Processing
PLoS ONE | www.plosone.org 2 May 2007 | Issue 5 | e427Figure 1. Exon 23 contains purine-rich elements that activate splicing of a heterologous substrate containing a weak 39 splice site. The sequence
of the first 90 nucleotides of dystrophin exon 23 is shown at the top of the figure. Arrows identify the natural mutation (CRT) occurring in the mdx
mouse and the mutations that disrupt the purine-rich region R1. The borders of the M1 element are defined by the homology (12 of 12 positions)
shared with the human dystrophin exon 23. Different regions of dystrohin exon 23 were inserted in the second exon of Dpy2, an enhancer-
dependent mRNA containing a weak pyrimidine stretch [60]. The structure of the chimeric pre-mRNA substrates subjected to in vitro splicing
reactions is shown at the bottom right of the figure. White boxes indicate Dpy2 exons, black boxes indicate different regions of the dystrophin exon
23, dashed boxes indicate portions of exon 23 not included in the substrates, white vertical lines indicate the mdx and R1 mutations. The gray box in
Dpy2E identifies the two splicing enhancers found in the a-tropomyosin exon 2 gene [60]. The structures and the mobility of the products and
intermediates of splicing are shown on the sides of the gel. D172-212D RNA was used as a positive control for D1-40D to rule out any exon size
inhibitory effect on splicing. Asterisks indicate the position of the spliced RNAs. Splicing reactions, carried out for 70 min at 30uC, were resolved on
a 12% denaturing polyacrylamide gel. Comparable results were obtained in three independent experiments.
doi:10.1371/journal.pone.0000427.g001
Dystrophin mRNA Processing
PLoS ONE | www.plosone.org 3 May 2007 | Issue 5 | e427mRNA splicing. Three-exon constructs, containing the genomic
sequence spanning from exon 22 to exon 24 and therefore
sensitive to mRNA surveillance, were employed to examine both
NAS and NMD activities. Translation start and termination
codons were inserted in frame with the dystrophin exons at the
beginning of exon 22 and at the end of exon 23 or 24 respectively.
Twenty-four hours after transfection, total RNA was isolated and
quantitative analyses were carried out on Northern blots
normalized to the internal control neomycin (see Materials and
Methods). As shown in Figure 4A, the mdx mutation decreased the
levels of RNA to ,50% (D22-23 mdx), while the R1 mutation
(D22-23 R1M) had a milder phenotype than predicted from the in
vitro splicing experiments (Figure 1, D90R1M), reducing the
processing of the D22-23 R1M RNA to ,85%. The observation
that the simultaneous presence of the two mutations had an
additive negative effect on splicing (D22-23 mdxR1M construct,
reduction to ,35%) probably reflect the previous finding that only
one splicing enhancer complex can interact with the spliceosome
components at any given time [64,65].
Since it has been shown that the trinucleotide GAG severely
slows down the second step of splicing in vitro [49,52], and in
different human genetic diseases is associated with aberrant
splicing phenotypes [51,53,54], we next investigated if the
presence of the ESE in the constitutive exon 23 is required to
activate the 39 splice site of intron 22 containing the rare G residue
at position 23. Mutant mini-genes carrying the canonical CAG
trinucleotide at the 39 splice site of intron 22 were generated and
their activity examined. As shown in Figure 4A, splicing increased
about 2 fold for both the wild-type and the mdx RNA (CAG exon
23 wt, CAG exon 23 mdx), but their relative abundance perfectly
matched the ratio observed in the GAG constructs (,50%
reduction for the mdx RNA). The possibility that intron 23 59 splice
site could enhance GAG recognition [66] was ruled out by the
analysis of the three-exon constructs carrying the trinucleotide
CAG. In this case, splicing stimulation, as well as comparative
RNA ratios, perfectly matched the results previously obtained with
the two-exon constructs (data not shown). Thus, as opposed to
other more specialized ESEs involved in the activation of non-
canonical 39 splice sites [67], exon 23 ESE appears to be
a constitutive element, not functionally dedicated to activate the
GAG located at the 39 splice site of intron 22.
Surprisingly, the presence of the mdx mutation had essentially no
effect on RNA abundance of the three-exon constructs as
determined by both Northern blot (Figure 4B D22-23-24 wt,
D22-23-24 mdx) and quantitative RT-PCR (Figure 4C left panel).
In addition, no levels of exon 23 skipped RNA were detected when
the radioactive PCR was carried out for 34 cycles (data not
shown). Moreover, Western blot analysis revealed that exon 22-23-
24 mRNA was competent for translation, producing a polypeptide
of about 20 kDa (data not shown). The discovery that the levels of
expression of the three-exon mini-genes (comparable, after
Figure 2. SR proteins bind exon 23 enhancer elements.
32P labeled
D90 RNA was incubated at 30uC for 10 min with purified SR proteins
prepared from calf thymus as previously described [63]. Binding
reactions performed in the absence or in the presence of increasing
concentrations of cold competitor RNAs (with molar excess of 30, 60, 90
and 120 fold, as indicated by the gradients above the gel lanes) were
fractionated on a 4% non-denaturing polyacrylamide gel. The
schematic representation of the RNAs is depicted as in Figure 1. The
positions of free RNA and bound complexes are shown. Comparable
results were obtained in two independent experiments.
doi:10.1371/journal.pone.0000427.g002
Figure 3. UV cross-linking of a 40 kDa SR protein to exon 23. A) Different
32P labeled RNAs represented as in Figure 1 were incubated at 30uC for
10 min with purified SR proteins. Following UV cross-linking and RNAse A/T1 digestion,
32P labeled proteins were analyzed by SDS-PAGE. Molecular
weight markers are shown on the left. B) Cross-linking of
32P labeled D90 RNA was performed in the presence of increasing amounts of cold
competitor RNAs (10 and 30 fold molar excess, as indicated by the gradients above the gel lanes). C) Coomassie–stained SDS-PAGE separated SR
proteins (7 mg). Comparable results were obtained in three independent experiments.
doi:10.1371/journal.pone.0000427.g003
Dystrophin mRNA Processing
PLoS ONE | www.plosone.org 4 May 2007 | Issue 5 | e427Figure 4. Splicing of dystrophin mini-genes in vivo. Cos 7 cells were transfected with plasmids expressing different portions of the genomic region
of the dystrophin gene spanning from exon 22 to exon 23/24. Northern blot analysis was carried out on total RNA prepared 24 hr after transfection,
as described in Materials and Methods. Band intensities, quantified by phosphorimager analysis, were normalized for transfection efficiency and RNA
recovery to the level of the co-expressed neomycin mRNA (neo). Normalized values were expressed as a percentage of wt mRNAs that were defined
as 100. The schematic structure of the substrates is shown on the right part of both panels A and B. Dystrophin exons are identified as in Figure 1. b-
globin exons are shown as gray boxes while the 59 and 39 UTRs as white thinner boxes. (A) Two exon mini-genes carrying dystrophin exons 22 and
23. (B) Three exon mini-genes carrying dystrophin exon 22 and 23 and 24, chimeric constructs, and the b-globin system (b2globin wt and b2globin
39 carrying a nonsense mutation at codon 39) used as a reference [81]. Comparable results were obtained in three independent experiments. (C) Left
panel: autoradiogram of a representative quantitative RT-PCR performed as described in Materials and Methods. The upper bands correspond to RT-
PCR products from dystrophin mRNA obtained with primers located in exons 22 and 24; the lower bands correspond to the neomycin gene used as
an internal control. 2and+lanes correspond to reactions carried out in absence or presence of reverse transcriptase. Right panel: non-quantitative RT-
PCR performed as described in Materials and Methods. Mobility of the predicted splicing products is shown on the right. The PCR product deriving
from skipping of exon 23 was not detected.
doi:10.1371/journal.pone.0000427.g004
Dystrophin mRNA Processing
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lower than those of the b-globin constructs (Figure 4B, compare
D22-23-24 wt with bwt), prompted us to investigate if mRNA
instability was interfering with NMD detection. To address this
issue, we built new hybrid constructs fused to the b-globin 39
UTR, that carries stabilizing cis-elements recognized by cytoplas-
matic RNP complexes [68]. To boost the efficiency of translation
we also linked the b-globin 59UTR and exon 1 to dystrophin exon
22 [69]. Examination of these constructs revealed a 3–4 fold
increase in RNA levels, with a significant reduction in the
abundance of the mRNA carrying the mdx mutation to ,60%
(Figure 4B, b22-23-24 wt and b22-23-24 mdx). Interestingly,
similar results were obtained in the presence of the b-globin
39UTR alone (22-23-24 39b constructs), while no effect on
dystrophin mRNA metabolism was detected in constructs carrying
the b-globin 59UTR alone (Figure 4B, 59b22-23-24wt and mdx).
Figure 5. SR proteins interact with dystrophin exon 22 and 24. A) Different SR proteins associate with exons 22 and 24.
32P labeled exon 22 and 24
RNAs, incubated with SR proteins were subjected to UV-crosslinking as described in Figure 3. Molecular weight markers are shown at the left; exon
22A and 24A correspond to the antisense RNAs used as controls. B) Exon 24, but not exon 22 activates splicing of the enhancer-dependent Dpy2
RNA. Different regions of dystrohin exon 22 (145 nt) and 24 (113 nt) were cloned in the second exon of the enhancer-dependent Dpy2 substrate. The
structure of the chimeric constructs subjected to in vitro splicing reactions is shown on the right of the panel, with black boxes indicating exon 22 and
24 and dashed boxes the portion of the corresponding exon not included in the pre-mRNA. A indicates the anti-sense orientation of each region,
while numbers after the slash indicate their nucleotide length. Dpy2 and Dpy2E are defined as in Figure 1. The structures and the mobility of the
products and intermediates of splicing are shown on both sides of the panel. Asterisks indicate the position of the spliced RNAs. The molecular weigh
of the band detected below the D24/60 RNA precursor does not correspond to the expected splicing product. In vitro splicing reactions were carried
out as in Figure 1. Comparable results were obtained in two independent experiments. C) Schematic representation of SR binding sites within
dystrophin exon 22 and 24 computed by ESEfinder [61,62].
doi:10.1371/journal.pone.0000427.g005
Dystrophin mRNA Processing
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detectable in the b-globin hybrid constructs either (Figure 4C,
right panel), support the hypothesis that reduction of dystrophin
mRNA observed in vivo is probably due to NMD.
The finding that the D22-23-24, but not the D22-23 mini-genes
constructs, were insensitive to the presence of the mdx mutation,
also indicates that the presence of intron 23 and exon 24
compensate for the partial inactivation of exon 23 ESE. The
hypothesis that splicing between exons 23 and 24 could
compensate for the mdx mutation by creating a new ESE [70]
was then examinated by testing RNA substrates containing
juxtaposed exons 23 and 24. Although RNA abundance was still
reduced by the mdx mutation, only a mild compensatory effect
(,10–15%) was observed with these constructs (data not shown).
SR proteins promote dystrophin exon bridging in
vitro
In addition to their involvement in the splicing reaction, SR
proteins and ESEs appear to mediate exon/exon association,
a process that, bringing exons into proximity, could facilitate
selection of the correct 59 and 39 splice sites [26,27]. In a gene like
dystrophin, characterized by large introns, exon-bridging could
play an important role before mRNA catalysis. Moreover, if not
affected by the mdx mutation, associations between exon 22, 23
and 24, could force the inclusion of exon 23 and prevent its
skipping.
To determine whether SR proteins interact with the constitutive
exons 22 and 24, we performed UV crosslinking experiments with
purified SR proteins, uniformly
32P-labeled exon 22 and 24 RNAs
and nonspecific cold competitor RNA,. This analysis revealed
that, in addition to a 40 kDa protein(s), exons 22 and 24 efficiently
interacted with two other SR proteins, migrating at ,34 kDa
(Figure 5A). Neither of these SR proteins cross-linked to the
antisense-exons used as controls for binding specificity (exon 22A
and exon 24A). Of the known SR proteins, ASF/SF2, SC35 and
9G8 migrate as 34 kDa peptides.
To determine whether SR proteins bound to the constitutive
exons 22 and 24 could also activate splicing in an enhancer-
dependent context, we cloned different regions of the two exons in
the Dpy2 pre-mRNA. As shown in Figure 5B, only the entire exon
24 was able to stimulate Dpy2 splicing quite efficiently. However,
it is important to keep in mind that the strength of each ESE is
determined by different parameters [65]. Thus, association of
particular SR proteins with constitutive exons can result in the
formation of complexes involved only in the basic splicing reaction
and not having enough potency for activating weak splice sites (see
Discussion).
We next asked whether SR proteins and ESEs could directly
promote dystrophin exon bridging in vitro. Biotinylated
32P-labeled
exon RNAs were incubated with non-biotinylated
32P-labeled
exon RNAs and purified SR proteins diluted to the same
concentration measured in splicing HeLa nuclear extract
(,30 mg/ml) [71]. Possible ternary complexes (biotinylated
exon/SR proteins/non-biotinylated exon) were purified with
streptavidin magnetic beads and, after extensive washing, RNA
was extracted and resolved on denaturing gels. This assay revealed
that exon/exon associations were efficiently promoted in the
presence of SR proteins. In fact, a substantial enrichment of co-
purified non-biotinylated exons (,10 fold over the experimental
background), was consistently detected after addition of SR
proteins to the reactions (Figure 6, compare lanes 8–11 with lane
12). However, neither the presence of the mdx mutation nor the
deletion of the R1 element affected the efficient formation of
complexes between exon 22, 24 and biotinylated exon 23 (Figure 6,
compare lanes 10 and 11 with lane 9). The specific formation of
ternary complexes is demonstrated by the findings that (i) in the
absence of SR proteins only biotinylated RNAs were purified
(Figure 6, lanes 5–7) and (ii) antisense exons 22 or 24, used as
negative controls and whose stability was not influenced by the
presence of the SR proteins (Figure 6, lanes 13 and 14), did not
associate with biotinylated exon 23. Thus, the bridging activity of
SR proteins, that in not impaired by the mdx mutation, could be
involved in counterweighing exon 23 skipping predisposition
caused by the combination of the mutation and the unusual
trinucleotide GAG.
DISCUSSION
The physical characteristics of the dystrophin gene provide
a unique model for expanding our knowledge of the mechanisms
and factors involved in splice site selection and RNA processing.
Dystrophin introns, some of which span more than 100 kb, appear
to be spliced during the 16 hours required to transcribe the entire
gene [72]. This coordinate activity probably provides an efficient
way to increase the local concentration of splicing factors nearby
the hnRNA, reduces the number of splice sites available and
ensures that exons are spliced in the correct 59 to 39 order [73].
However, little is known about the factors and the cis-elements
involved in dystrophin mRNA splicing.
In this study, we report that in the mdx mouse the presence of
a nonsense mutation in exon 23 partially inactivates a multisite
exonic splicing enhancer. Although this event could cause exon
Figure 6. SR proteins mediate associations of exons 22, 23 and 24.
Biotinylated and non-biotinylated dystrophin exons labeled with
32P-
ATP (sense exons) or
32P-UTP (antisense exons), were mixed with
purified SR proteins. Following incubation, biotinylated RNAs were
purified with streptavidin magnetic beads and the formation of RNA
complexes was analyzed on 10% denaturing polyacrylamide gel.
Asterisks and A indicate biotinylated and antisense exons respectively.
Lanes 1 and 2, showing the relative migration of exons 22, 23 and 24,
contain one-fourth of the RNA inputs assayed in lanes 8–11 and 13–14
respectively. Lane 15 and 16 contain one-fourth of the supernatants
collected from reactions loaded in lanes 13–14. Background levels,
probably generated by non-specific trapping of RNA or RNA/protein
complexes into the magnetic beads, are shown in lanes 3, 4, and 12 and
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carrying the nonsense mutation is degraded by activation of the
NMD pathway. Here we provide evidence that exon 23 contains
multiple binding sites for a 40 kDa SR protein. The M1 element is
highly conserved between both human and mouse dystrophin
genes (12 out of 12 positions), while R1 matches a splicing
enhancer that was previously identified by in vitro functional
iterative strategies [16,18]. Several SR binding sites having
enhancing activity have also been identified and studied in the
constitutive b-globin exon 2 [29], and other observations have
demonstrated a linear correlation between splicing efficiency and
the number of enhancer elements present [65]. Our data are in
agreement with this model and also show the functional flexibility
of adjacent ESEs. In fact, while both M1 and R1 were necessary to
activate splicing of the enhancer dependent Dpy2 construct, in the
context of the dystrophin gene, intron 22 removal is mainly
dependent on the activity of M1. Nonetheless, in the presence of
the mdx mutation, R1 could play an important role as a back-up
element, which partially compensates for the lack of M1 activity.
By UV cross-linking and band shift experiments, we have shown
that both M1 and R1 can be specifically recognized by a 40 kDa
SR. Although both Tra 2a/b and SRp40 migrate at ,40 kDa,
Tra 2 is not present in purified preparations of SR proteins [74],
therefore SRp40 should be the only protein that binds exon 23
ESE.
In this paper we also show that exon 23 ESE activity is not
functionally linked to the rare GAG present at the 39 splice site of
intron 22. Two lines of evidence support this conclusion: i) two
exon mini-genes carrying the most efficient CAG were still equally
sensitive to the mdx mutation, and ii) in the human dystrophin gene
M1 is conserved, while the GAG is replaced by CAG. By
quantitative RT-PCR employing different exon/intron primers
[75], we found that splicing of a mini-gene carrying exons 22, 23,
and 24 did not follow the first-come, first-served model. Neverthe-
less, intron 23 was spliced before intron 22 in only 50% of the
molecules. At an RNA polymerase average elongation rate of
2.4 kb min
21 [72], intron 22 39 splice site becomes available for
splicing just a minute before intron 23 39 splice site synthesis.
Therefore, we believe that lack of linear progression in intron
removal is not caused by a severe delay promoted by the GAG.
Our mini-gene analysis also rules out the possibility that the
16 hours necessary to transcribe a gene as large as dystrophin
could provide enough time for intron 22 removal, even with its
slow kinetic of cleavage. Our results indicate that in vivo, removal
of dystrophin intron 22 is not subjected to the same functional
limitations observed previously in vitro [49], and support the
hypothesis that the use of natural GAG 39 splice sites could be
forced by the absence of downstream competing CAGs [52], as in
the case of dystrophin exon 23 (data not shown). The lack of cross-
talk between ESEs and GAG could explain why just a small
minority of natural 39 splice sites contain a GAG while ESEs
appear to be present in most exons.
Here we also show that the SR proteins can directly promote in
vitro exon/exon association between the constitutive dystrophin
exons 22, 23 and 24. Alternative splicing of the chicken cardiac
troponin T (cTnT) gene appears to be modulated through exon/
exon interactions mediated by SR proteins [27], and ESEs are
required for mammalian trans-splicing [76]. Our data show that in
vitro, the formation of a ternary complex between SR proteins and
different dystrophin exons occurs efficiently and is not influenced
by the presence of the mdx mutation. Interactions of exon 22, 23
and 24 mediated by SR proteins, could hold the dystrophin pre-
mRNA in a topological configuration that imposes the use of
intron 22 39 splice site. Pre-splicing physical interactions between
exon 23 and 24 could increase the local concentration of ESEs
around intron 22 39 splice site [65] and compensate for the
damaging effects of the mdx mutation. Thus, the splicing
stimulation observed with the three-exon constructs (Figure 4A)
could derive from the combined action of the ESEs contained in
the two unspliced exons.
In the dystrophin gene, selection of committed splice sites often
separated by long distances (.100 kb) could be achieved by intron
looping promoted by redundant ESEs situated in constitutive
exons that are not functionally subordinated to splice sites strength
or distance. Interestingly, this mechanism has been also proposed
for several hnRNP proteins bound to intronic sequences [77–79].
The finding that purine rich regions with a wide spectrum of
enhancing activity have been identified in several other dystrophin
exons [31] indicates that ESEs could be common elements along
the gene and could share the same bridging properties of the ones
we have analyzed. Thus, optimization of therapeutic antisense
oligonucleotides promoting exon skipping and preventing the
incorporation of nonsense mutations in the mature dystrophin
RNA should take into account both the complex crosstalk between
ESEs, SR and pre-mRNA and potential exon/exon associations.
MATERIALS AND METHODS
DNA constructs
The dystrophin genomic region spanning exons 22, 23 and 24 was
amplified from wild type and mdx genomic DNAs with ExpandTM
Long template PCR system (Roche) and cloned in the EcoRV site
of both pcDNA3.1(+) and pcDNA3.1/Myc-His(2)A( Invitrogen).
The translation start and termination codons were inserted in
frame with the dystrophin exons at the beginning of exon 22 and
at the end of exon 23 or 24 during the PCR reaction. Minigenes
were fused to the 39 UTR of bovine growth hormone carried by
the cloning vectors. Single dystrophin exons were cloned into the
PstI site of pUC18-Dpy2 [60], generating Dpy2/22, Dpy2/23wt,
Dpy2/23mdx and Dpy2/24 plasmids. Mutant constructs were
prepared by inverse PCR [80] with appropriate oligonucleotide
pairs. Templates for in vitro RNA transcription were generated by
PCR using primers containing the T7 transcription initiation
sequence in the 59 oligonucleotides. Human b-globin reporter
plasmids bwt and b39 were as described [81]. All oligonucleotide
sequences and cloning strategies are available upon request.
DNA transfection
COS 7 cells were grown in 100 mm dishes containing DMEM
(Gibco-BRL) supplemented with 10% fetal bovine serum (Gibco-
BRL). Transfections were carried out with 3 mg of each construct
using Lipofectamine reagent (Gibco-BRL) according to the
manufacturer’s instructions. RNA was isolated 20 hr after trans-
fection.
RNA extraction, Northern Blot and RT-PCR
Total RNA was isolated from cultured cells using TRI RE-
AGENT (Molecular Research Center, Inc.) according to the
manufacturer’s instructions. Northern Blot analysis was performed
as previously described on 10 mg of total RNA [82]. Blots shown in
Figure 4 were hybridized with oligonucleotide 24E complemen-
tary to dystrophin exon 24 (59-TCTGCATTGTTTGAGCTG-
TTTTT-39), and oligonucleotide 2glo complementary to b-globin
exon 2 (59-CACTAAAGGCACCGAGCACTTT-39). Oligonucle-
otide 22E complementary to dystrophin exon 22 (59-CTGTA-
ATTTCCCGAGTCTCTCC-39), and oligonucleotide 23E com-
plementary to dystrophin exon 23 (59-CTGAAATTTTCGAAG
TTTATTC-39) were also used to confirm the results obtained with
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AAGGTGAGATGACAGGAGATC-39) was used to normalize
the blots to the internal control neomycin. Band intensities were
quantified by phosphorimager analysis (Storm 860 image analyzer,
Molecular Dynamics). For RT-PCR analysis, total RNA was
treated with DNase I Amp Grade (Gibco-BRL) and cDNA
synthesized with random hexamers (Gibco BRL) and SUPER-
SCRIPT II reverse transcriptase (Gibco BRL) according to the
manufacturer’s instructions. For quantitative amplification
(Figure 4C, left panel) PCR reactions were carried out in the
presence of a
32P dCTP as previously described [83] with primers
22E, 22E5 (59-TTTTTGACACTTTACCACC AAT-39), 24E,
Neo5 (59-TGAATGAACTGCA GGACGAGG-39) and Neo3.
PCR reactions were analyzed on 8% acrylamide gels after 10, 15,
20 35 cycles and bands quantified by phosphorimager analysis.
The non-quantitative PCR carried out to monitor exon 23
skipping (Figure 4C, right panel), was performed with oligonucleo-
tides 22E and 24E (35 cycles). PCR reactions were assessed on
a 1.2% agarose gel and stained with EtBr.
In vitro transcription and splicing reactions
Capped
32P–labeled RNAs were synthesized with T7 RNA
polymerase, as previously described [84]. Unlabelled competitor
RNAs were prepared using the MEGAscript
TM T7 Kit (Ambion)
following the manufacturer’s instructions. Standard splicing
reactions contained 20–40 fmol of
32P-labelled RNA transcript,
2.2 mM MgCl2, 0.5 mM ATP, 20 mM creatine phosphate,
1000 U/ml Rnasin (Promega) and 40% nuclear extract. Splicing
products, fractionated on 12% polyacrylamide (acrylamide:bisa-
crylamide 20:1)/8M urea gels, were quantified by phoshorimager
analysis.
SR proteins
SR proteins were purified as previously described [63]. Gel-shift,
UV cross-linking, and exon bridging assays were carried out with
a final SR protein concentration of ,30 mg/ml, corresponding to
the one measured in HeLa splicing nuclear extracts [71].
Gel-shift assay
Binding reactions for the gel-shift assays, containing purified SR
proteins [63], 100 fmol RNA, 5 mg/ml heparin, 20 mM HEPES
pH 8, 5% glycerol, 70 mM KCL and 3 mM MgCl2, were
incubated at 30uC for 10 minutes. Cold competitor RNAs were
pre-incubated with SR proteins for 5 minutes prior to the addition
of radiolabeled substrates. Complexes were fractionated on 4%
polyacrylamide gels (acrylamide/bisacrylamide 80:1), 5% glycerol,
0.56TBE. Signals were quantified by phoshorimager analysis.
UV cross-linking
UV cross-linking experiments were carried out as for the gel shift-
assay, except that heparin was omitted from the reactions and
RNA samples were labeled with ATP. After 10 minutes in-
cubation at 30uC, reactions were transferred in a 96-well
microtiter dish (Falcon Micro Test III
TM), placed directly under
a 254-nm UV light at 5 cm from the bulb, and irradiated for
10 minutes. RNAse A (1mg/ml) and T1 (10U) were then added
and the reactions were incubated for 15 minutes at 37uC.
Samples, adjusted to 40 mM Tris (pH 6.8), 7% glycerol, 1.5%
SDS and 400 mM 2-mercaptoethanol, were then fractionated on
12% SDS-PAGE gel. Signals were quantified by phoshorimager
analysis.
Exon bridging assay
Biotinylated RNAs were prepared as capped
32P–labeled RNAs,
except that ATP or UTP were used as radiolabeled nucleotides for
sense or antisense exons respectively and the concentrations of
both CTP and Biotin-14-CTP (Gibco-BRL) were 250 mM. Before
use, 0.6 mg of Streptavidin MagneSphereH Paramagnetic Particles
(Promega) were both washed (3 times with 1ml) and resuspended
(100 ml) in buffer W (20 mM HEPES, 100 KCL, 3 mM MgCl2,
5 mg/ml tRNA, and 20 mg/ml BSA). Exon/exon interactions
were carried out in 10 ml reactions containing 20 mM HEPES,
100 KCL, 3 mM MgCl2, 20 units of RNasin (Promega),
equimolar amounts of biotinylated and nonbiotinylated RNAs
(200 fmoles each) and purified SR proteins (,30 mg/ml). After
incubation at 30uC for 10 minutes, streptavidin beads were added
and reactions incubated at 4uC for 1 hour with nutation. Beads
were then collected by magnetic stand (Promega), and while the
aqueous fractions were phenolized and then ethanol precipitated,
beads were washed 4 times with 1 ml of buffer W containing
0.05% Triton-X-100 and then resuspended in 100 ml of elution
buffer (1% SDS, 1 mM EDTA, 50 mg/ml tRNA). Samples were
incubated at 90uC for 5 minutes, beads collected and super-
natants, containing the released RNAs, extracted with phenol/
chloroform and ethanol precipitated. RNAs were analyzed on
10% polyacrylamide-8M urea gels. Signals were quantified by
phoshorimager analysis.
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